Employees

Implantica's employees are building a future with technologically advanced solutions for large unmet needs in healthcare



Employees

A shared vision

Implantica's vision is to become the world leader in smart medical implants and breakthrough surgical products. To reach that goal, we embrace the fact that the talent and caliber of our people is fundamental to achieve it. People come to Implantica because they believe they can be a part of an exciting journey that revolutionizes patient care for debilitating conditions across a range of disease states, using cutting edge technology. This shared vision has att-racted world-class talent from diverse leading organizations such as NASA, Medtronic, Ericsson, as well as from leading universities around the world.

Core values de ine our culture and how we work

At Implantica, we realize that how we work can be as im-portant as what we do. To guide us, all employees are held accountable on an annual basis to embody a set of values including collaboration, inclusion and modeling integrity. We encourage being creative, acting bold, and moving with speed and innovation. Together, these values and ways of working shape who we are and create a foundation to be successful as an expanding international organization.

A decentralized, lexible, next-generation working environment

Currently, 115 people are working for Implantica, 32 of whom were employed, another 32 employee-like, on long-term contractual basis, 46 men and 18 women plus 51 R&D consultants. The company has offices in Switzerland, Liechtenstein and Malta, with employees also working across Europe and the United States.

Implantica supports a modern flexible workplace en-vironment, with a balance of working remotely and in the office to suit personal situations. We believe personal connection and collaboration can be achieved through modern remote communication tools and platforms, in addition to in person working, so that both the business and individuals can thrive.

As Implantica grows, processes and new norms will grow with us for continuous improvement, but the decen-tralised and flexible working environment will remain a part of who we are. Combined with operating with a strong set of values, we believe this increases productivity, personal well-being, and job satisfaction.







Successful IPO on NASDAQ First North, September 2020

Founder specialist surgeon educated at Karolinska

- ✓ Successful track record in the implant business
- Developing the gastric band business to 28% non-US market share
- ✓ Founder invested SEK 800 million in Implantica

The previous invention/venture the adjustable gastric band – a highly successful product



Source: (1) Angrisani L, et al., 2003/2008/2011/2013; Obesity Surgery 2004/2009/2013/2015; Scopinaro N, 1998: (2) LINX magnetic band and Endostim average.

Board of Directors



Born: 1959

Education: Master of Business Administration from IMD Business School in Lausanne, Switzerland: Master's Degree, Mathematics and Statistics from the University of Oslo, Norway.

Background: Liselott Kilaas has around twenty years of international management experience and a background in strategic and operational performance development across a broad spectrum of businesses. She has further extensive non-executive board and audit committee experience from the Central Bank of Norway and sectors such as Telecommunication, Media and Shipping and was awarded the Norwegian 2019 Women's Board Award.

Current positions: Chair of the board of directors of Avonova AB, board member in Ambea AB (publ), Orkla ASA (publ), Peab AB (publ), Folketrygdfondet, Norsk Hydro (publ), MRH-Blikk and Recover Nordic.

Holdings in Implantica (including related parties): Liselott Kilaas holds no SDRs or warrants in the company, however, she has a 5-year share program of 28,135 SDRs.



Johan Bois

Born: 1964 Education: LL. M. University of Stockholm; Bachelor of Business University of Gothenburg; Professional Board Member Course, Michaël Berglund Institute in Stockholm.

Background: Johan Bojs is an experienced attorney specializing in tax and commercial law.

Current positions: Partner at ASTRA Law Firm, Chair of the board of directors in Mirola Holding AB and NEW International Investments AB. Board member in Cornerstone Group AB, Olero Invest AB, Olero Lodge AB, Astragruppen Advokat AB, Asellus Holding AB, Olero IP AB and Olero Konsult (holder).

Holdings in Implantica (including related parties): Johan Bojs owns 132,362 SDRs in Implantica AG through his insurance policy.

Tomas Puusepp Board member

Born: 1955



Education: Electrical Engineer, studies in Physics at the Royal Institute of Technology in Stockholm and at the University of Stockholm and Management (IEP) at IMD in Lausanne.

Background: Tomas Puusepp has held various positions at the Research Institute for Nuclear Physics, Scanditronix and Ericsson before being employed by Elekta in 1988. Since then, he has held various management positions, including head of Elekta's neurosurgery operations, President of Elekta's subsidiary in North America, global head of Elekta's sales, marketing and service operations, and President and CEO of Elekta during fiscal years 2005/06 to 2013/14, and during 2015/16.

Current positions: Board member of Permobil Holding AB, Sectra AB (publ), Instoria Sweden AB, Instoria Invest AB. Elekta Foundation and board member and CEO of Investest AB.

Holdings in Implantica (including related parties): Tomas Puusepp owns 20,000 SDRs in Implantica AG.

Board of Directors





Born: 1957

Education: Studies at the Conservatory for Music, Bern (CH), Music Teacher Diploma. Studies at the Conservatory for Music in Geneva, Virtuosité, Soloist Diploma; Postgraduate Studies, Nordwestdeutsche Musikhochschule, Detmold, Germany.

Background: Stephan Siegenthaler co-developed a gastric band (SAGB) business into a multinational company, eventually commanding approximately 28 per cent of the obesity surgery market outside of the US over a six-year period and was sold to Johnson & Johnson for a significant amount. He focused primarily on building the sales organization, created an extensive and critical surgical and hospital network, recruited high-performing salespeople, and established an in-house sales force in 32 countries.

Current positions: Stephan Siegenthaler has no other ongoing assignments.

Holdings in Implantica (including related parties): Stephan Siegenthaler owns 900,000 SDRs in Implantica AG.



for Foreign Medical Graduates).

Born: 1945

Education: PhD, University of Bern, Switzerland and ECFMG Certificate (Educational Commission

Background: Prof. Dr. Klaus Neftel is a certified haematologist and specialist in Internal Medicine. Former Chief of Internal Medicine at the Zieglerspital, Bern, Professor at the University of Bern, Founder of Medtec AG, a continuous medical education program. He has been awarded the Swiss Society for Internal Medicine 1983, 1988, 2002 and the Swiss Society for Haematology 1983.

Current positions: Editor Swiss Medical Forum (EMH Swiss Medical Publishers Ltd.); independent medtech investment advisor.

Holdings in Implantica (including related parties): Klaus Neftel owns no shares. SDRs or warrants in the company.

Management

Dr. Peter Forsell Founder and CEO since inception



Born: 1954

Education and experience: Peter Forsell is a medical doctor educated at Karolinska Institute and specialist surgeon at Karolinska Hospital. He also has additional finance and legal education. Dr. Peter Forsell is the Co-founder of Obtech Medical AG, where he also was Executive Chairman of the Board. He developed the Swedish Gastric Band (SAGB) and turned it into an international business, capturing 28 per cent of the obesity surgery market outside of the US. In 2002, in an early stage before US FDA approval, the business was sold to Johnson & Johnson for CHF 175m. After the sale, the total gastric band market peaked at 40 per cent of the world market. From the corporate journey with Obtech, he gained valuable experience in medical device product development, regulatory approval, and building a multinational corporation, including a sales organisation in 32 countries.

Dr. Forsell is a serial inventor and has created most of Implantica's IP with many new breakthrough medical implants. His inventions are covered by an extensive patent portfolio of over one thousand patent cases including Implantica's wireless energising and eHealth platforms.

Dr. Peter Forsell funded the R&D activities of Implantica with the proceeds from the sale of Obtech Medical and has invested more than SEK 800 million in Implantica.

Holdings in Implantica (including related parties): Peter Forsell owns 21,616,770 SDRs and 1,125,000,000 class B shares in Implantica AG.

Andreas Öhrnberg Chief Financial Officer since 2020*

Born: 1978

Education and experience: Andreas Öhrnberg has a dual M.Sc. (Stockholm School of Economics, Stockholm University) and is a Chartered Financial Analyst.

He has over 15 years of experience in senior finance and general management positions. Before joining Implantica in 2020, He served as CFO at Talkpool, a publicly listed technology group domiciled in Switzerland.

Previously, Andreas Öhrnberg was Vice President Finance & Strategy at Swiss Re, a global Fortune 500 company.

Holdings in Implantica (including related parties): Andreas Öhrnberg owns no shares or SDRs in the company. He has a share program in the company totaling 87,169 shares vesting over a five-year period.



Nicole Pehrsson Vice President Operations & Investor Relations since 2016*

Born: 1966

Education and experience: Bachelor of Arts in Economics, University of California, Los Angeles (summa cum laude). Nicole Pehrsson has strong financial experience in corporate finance and equity research. In Switzerland, Nicole worked as an equity research analyst at EFG Bank AG, Zurich, and before that as a business developer in the Corporate Finance team of JP Morgan, Zurich. In the US, she worked as an analyst in the Corporate Finance Group of Kidder, Peabody & Co. Inc. in Los Angeles and Boston, Extracurricular financial activities involved – among others – appointed to Investment Advisory Board of the City of Huntington Beach (CA) and the Boston Women's Fund in Boston (MA).

Holdings in Implantica (including related parties): Nicole Pehrsson owns 481,417 SDRs in Implantica AG and has a share program for 42,400 shares vesting over a five-year period. **Stephan Siegenthaler** Chief Strategy Officer and board member since inception^{*}



Born: 1957

Education and experience: Studies at the Conservatory for Music, Bern (CH), Music Teacher Diploma. Studies at the Conservatory for Music in Geneva, Virtuosité, Soloist Diploma; Postgraduate Studies, Nordwestdeutsche Musikhochschule, Detmold, Germany.

Stephan Siegenthaler co-developed a gastric band (SAGB) business into a multinational company, eventually commanding approximately 28 per cent of the obesity surgery market outside of the US over a six-year period and was sold to Johnson & Johnson for a significant amount. He focused primarily on building the sales organisation, created an extensive critical surgical and hospital network, recruited high-performing salespeople and established an in-house sales force in 32 countries.

Holdings in Implantica (including related parties): Stephan Siegenthaler owns 900,000 SDRs in Implantica AG.

Management

Amit Kukreja Chief Market Access & Strategy Officer since 2021

Born: 1983



Education and experience: MBA from WHU Germany and a Mechanical Engineering Degree from Manipal Institute of Technology. Amit Kukreja has 15 years of extensive global medtech industry and strategy experience. He has served in several worldwide and regional leadership and advisory roles, driving and shaping reimbursement, health economics, clinical evidence planning, payer relations and upstream marketing & communications for disruptive medtech products.

Before joining Implantica in 2021, Amit served as Vice President of Corporate Market Access at Masimo Corporation, a global leader in innovative noninvasive patient monitoring technologies. Before that, he was the Vice President of Global Marketing, Reimbursement & Patient Access at Second Sight Medical Products, a global leader in neuromodulation implant devices for blindness. Juliette Cook Vice President Quality & Regulatory Affairs since 2021

Born: 1971



Education and experience: Ph.D. in Materials/Mechanical Engineering from University of Exeter and M.Sc. in Biomedical Engineering from University of Durham.

Juliette Cook brings over 20 years of quality and regulatory affairs experience having most recently been responsible for Regulatory Affairs for EMEA at Cochlear, an active implantable hearing solutions company. Prior to Cochlear, she was Director of Quality, Clinical & Regulatory Affairs at Rayner Intraocular Lenses Ltd. where she established the QA & RA department. Juliette is also an expert in EU Medical Device Regulation, regularly presenting and teaching the subject at industry events and conferences.